ClinicalTrials.gg
RecruitingNCT06640283ANAUpdated Dec 24, 2025

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

A Phase 2 interventional study of ctDNA test and Pembrolizumab in HPV-Related Carcinoma, Uterine Cervical Cancer and Anal Canal Cancer, sponsored by Instituto do Cancer do Estado de São Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Instituto do Cancer do Estado de São Paulo · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing pembrolizumab in Uterine Cervical Neoplasms — 11 open to participants now, 12 under way, 2 of them phase 3. pembrolizumab · Uterine Cervical Neoplasms.

Planned enrollment
9th of 25
150 · median 94
Started
2025
with 3 others
Phase 2
15 of 25
6 open now
Primary completion
2026-12
later than 1 of 11 live
Registered
19th of 25
by date
Lead sponsor
1 of 25
Instituto do Cancer do Estado de São Paulo

Among the 25 studies testing pembrolizumab in Uterine Cervical Neoplasms, this one is the 9th largest by planned enrollment, is one of 4 that started in 2025, is one of 15 in phase 2, reaches primary completion later than 1 of the 11 other live ones, and was the 19th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

11 of the 25 studies testing pembrolizumab in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing pembrolizumab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence. Due to the local inflammatory process post-treatment, response assessment by imaging (current gold standard) is limited, often necessitating multiple follow-ups and repeated invasive biopsies. Conventional follow-up is complex and costly, requiring equipment from secondary and tertiary services, trained radiologists, and patient exposure to radiation and contrast.

In this context of human papillomavirus(HPV)-related neoplasms, recent studies have demonstrated the role of ctDNA (circulating tumor DNA) in assessing the risk of recurrence or disease progression, providing a rationale for using the tool in two fronts:

  • Optimizing follow-up based on serial monitoring of ctDNA;
  • Selecting patients with positive ctDNA after RT, who are at high risk of recurrence, for treatment intensification.

Monitoring with ctDNA as a standalone follow-up tool in cases evolving with negative ctDNA after RT has the potential to replace imaging exams, being a minimally invasive test performed on a peripheral blood sample. Currently, ctDNA testing has expensive methodologies not available in the Unified Health System (SUS). This project aims to develop a methodology for ctDNA evaluation focused on HPV ctDNA research that is low-cost and executable in SUS, as well to assess the accuracy of this test in the population with HPV-related tumors.

Additionally, we will evaluate whether the early introduction of immunotherapy in patients with positive ctDNA after definitive treatment can increase cure rates. Immunotherapy already has a well-defined role in the treatment of metastatic HPV-related neoplasms. Recently, the use of anti-programmed death-1 (anti-PD1) has also shown benefits in patients with locally advanced cervical cancer with a high risk of recurrence who are candidates for chemoradiotherapy (CRT). Therefore, its use focused on HPV-related tumors, as well as a better understanding of which patients benefit from this strategy, warrants further investigation.

Read the detailed description

The ANA study is a research project aimed at enhancing the treatment and outcomes for patients with cervical and anal canal cancer by using innovative diagnostic and therapeutic methods. The study consists of the following phases:

  • Patient identification and selection;
  • Recruitment of patients diagnosed with cervical or anal canal cancer who are candidates for treatment with radiotherapy (RT), with or without chemotherapy: patients will be selected based on specific criteria to ensure a representative cohort;
  • Development and validation of the ctDNA HPV Test: development of a sensitive and specific test to detect HPV DNA in the blood. This test will undergo rigorous validation to ensure its accuracy and reliability;
  • ctDNA monitoring: blood samples collection from patients during treatment and follow-up. ctDNA levels will be monitored in real-time to early detection of residual or recurrent disease. This non-invasive method aims to provide a more accurate assessment of treatment efficacy and disease progression. The results of ctDNA will be compared with traditional imaging methods.
  • Complementary immunotherapy treatment: patients with positive ctDNA results after (chemo)radiotherapy will be considered for additional immunotherapy. This phase will evaluate the benefits of combining immunotherapy with standard (chemo)radiotherapy in order to improve patient outcomes;
  • Follow-up and outcome evaluation: long-term follow-up of patients to assess clinical outcomes, including survival and quality of life.

The ANA study aims to set new standards in the follow-up and management of HPV-related cervical and anal canal cancer by improving patient care within the Brazilian public health system (SUS).

03

Conditions studied

  • HPV-Related Carcinoma
  • Uterine Cervical Cancer
  • Anal Canal Cancer
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Cervical Carcinoma

Keywords

  • HPV
  • ctDNA
  • Cervical tumors
  • Anal canal tumors
  • Molecular diagnosis
  • Diagnostic test
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological diagnosis of anal canal or cervical cancer.
  2. Documented presence of HPV.
  3. Locally confined or locally advanced disease, defined as:

    1. Anal canal carcinoma stage I to III, according to American Joint Committee on Cancer (AJCC) 8th edition;
    2. Cervical carcinoma stage I B2 to IV A, according to AJCC 8th edition.
  4. Indication for definitive treatment with radiotherapy, with or without concomitant chemotherapy.
  5. (ECOG)-Performance Status (PS) 0 - 1.
  6. Age ≥ 18 years.
  7. Signing of the Form (ICF).
  8. -positive patients may be included if Cluster of Differentiation 4(CD4) count is greater than or equal to 200.
  9. Patients may participate in other concurrent studies, as long as they do not involve interventions related to the treatment of the underlying cancer.

Exclusion criteria

Exclusion Criteria:

  1. Patients with unequivocal distant at diagnosis.
  2. For participants with positive ctDNA after treatment, those candidates for participation in Phase II will be excluded if there is unequivocal radiological progression in the first imaging exam after the completion of radiotherapy (with or without chemotherapy) or routine indication for salvage surgery immediately after the conclusion of definitive treatment.
  3. Need for recurrent blood transfusions, such as weekly frequency.
  4. Another uncontrolled disease representing a life risk, as determined by medical judgment.
  5. Personal history of another active invasive malignant neoplasm in the last 5 years, except for non-melanoma skin carcinomas and in situ carcinomas.
  6. Pregnant individuals.
  7. Active opportunistic infection or disease.
  8. History of diseases.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Active laboratory monitoring

    Phase I Monitoring through collection of laboratory tests

    Diagnostic Test: ctDNA test

  • Experimental
    Intervention with Immunotherapy

    Phase II for participants who are ctDNA positive after standard treatment. Intervention will be with Pembrolizumab

    Drug: Pembrolizumab

Interventions

  • Diagnostic testctDNA test

    ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.

  • Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.

06

What researchers measure

Primary outcomes

  1. General Objective

    The objective of this study is to develop and validate a low-cost ctDNA test focused on detecting HPV-associated ctDNA for use in patients within the Brazilian Unified Health System (SUS). The test will be evaluated for its effectiveness in improving traditional monitoring methods and guiding the intensification of adjuvant treatment for anogenital neoplasms, including anal canal and cervical cancer. The impact of the test will be measured by correlating ctDNA detection with clinical outcomes of patients over time.

    Time frame: 2 years

Other outcomes

  1. Number of HPV-focused ctDNA tests developed and validated

    Measure the number of HPV-related ctDNA tests developed and validated for detecting HPV ctDNA in patients with anogenital neoplasms.

    Time frame: 2 years

  2. Performance of the validated HPV-related ctDNA test

    Measure the accuracy and specificity of the validated HPV-related ctDNA test, including the assessment of HPV typing, ctDNA, and HPV E6\*I messenger ribonucleic acid (mRNA) levels in the study population.

    Time frame: 2 years

  3. Comparison of accuracy between standard ctDNA and HPV-focused ctDNA

    valuate the accuracy of standard ctDNA compared to HPV-focused ctDNA and in relation to standard radiological control, based on routine imaging, through serial testing of ctDNA and HPV ctDNA after completion of treatment with definitive radiotherapy or chemoradiotherapy.

    Time frame: 2 years

  4. Comparison with Commercially Available HPV ctDNA Tests

    Compare the diagnostic accuracy of standard ctDNA with HPV-focused ctDNA and standard radiological control, using routine imaging and serial ctDNA tests after definitive treatment with radiotherapy or chemoradiotherapy.

    Time frame: 2 years

  5. Comparison of performance between the locally developed HPV ctDNA test and commercially available tests

    Compare the sensitivity, specificity, and overall performance of the locally developed HPV ctDNA test with commercially available tests on the market.

    Time frame: 2 years

  6. Direct costs of the ctDNA test

    Measurement of the costs associated with performing the ctDNA test, including materials, labor, and technology used.

    Time frame: 2 years

  7. Disease progression reduction rate with the use of immunotherapy

    Measure the rate of disease progression reduction in patients with positive ctDNA after definitive treatment, in response to the use of immunotherapy.

    Time frame: 2 years

  8. Influence of PD-L1 expression and HPV type on immunotherapy response

    Relationship between PD-L1 expression levels and HPV types on the immunotherapy response in patients with positive ctDNA. PD-L1 levels will be quantified using immunohistochemistry, and the HPV types present in tumor samples will be categorized. The outcomes will include the treatment response rate and progression-free survival, recorded over a two-year period.

    Time frame: 2 years

  9. Correlation between PD-L1 expression and HPV type with immunotherapy response

    Measure the correlation between PD-L1 expression and HPV type with the response rate to immunotherapy in patients with positive ctDNA, quantifying the impact of these variables on the effectiveness of immunotherapy.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Instituto do Câncer do Estado de São Paulo - ICESP
    São Paulo, 01246-000, Brazil
    Recruiting
    • Research Center, Assistant · Contacticesp.pesqclinica@hc.fm.usp.br · +55 11 3893-3566
    • Maria DP Estevez Diz, Doctor · Principal investigator
    • Camita MV Moniz, Doctor · Sub investigator
    • Leticia V Leis, Doctor · Sub investigator
    • Pedro Hashizume, Doctor · Sub investigator
08

References and documents

Publications

  • Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bieche I, Pierga JY, Buecher B, Meurisse A, Francois E, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S. Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clin Cancer Res. 2019 Apr 1;25(7):2109-2115. doi: 10.1158/1078-0432.CCR-18-2984. Epub 2018 Nov 30. PubMed 30504426 ↗
  • Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PubMed 24553385 ↗
  • Cabel L, Bonneau C, Bernard-Tessier A, Hequet D, Tran-Perennou C, Bataillon G, Rouzier R, Feron JG, Fourchotte V, Le Brun JF, Benoit C, Rodrigues M, Scher N, Minsat M, Legrier ME, Bieche I, Proudhon C, Sastre-Garau X, Bidard FC, Jeannot E. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open. 2021 Jun;6(3):100154. doi: 10.1016/j.esmoop.2021.100154. Epub 2021 May 19. PubMed 34022731 ↗
  • Jeannot E, Becette V, Campitelli M, Calmejane MA, Lappartient E, Ruff E, Saada S, Holmes A, Bellet D, Sastre-Garau X. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol Clin Res. 2016 Jun 28;2(4):201-209. doi: 10.1002/cjp2.47. eCollection 2016 Oct. PubMed 27917295 ↗
  • Jeannot E, Latouche A, Bonneau C, Calmejane MA, Beaufort C, Ruigrok-Ritstier K, Bataillon G, Larbi Cherif L, Dupain C, Lecerf C, Popovic M, de la Rochefordiere A, Lecuru F, Fourchotte V, Jordanova ES, von der Leyen H, Tran-Perennou C, Legrier ME, Dureau S, Raizonville L, Bello Roufai D, Le Tourneau C, Bieche I, Rouzier R, Berns EMJJ, Kamal M, Scholl S. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clin Cancer Res. 2021 Nov 1;27(21):5869-5877. doi: 10.1158/1078-0432.CCR-21-0625. Epub 2021 Jul 1. PubMed 34210686 ↗
  • Lefevre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers (Basel). 2021 May 18;13(10):2451. doi: 10.3390/cancers13102451. PubMed 34070045 ↗

Individual participant data

Plan to share: No — It has been decided not to share individual participant data (IPD) related to the study for several reasons. Protecting the privacy of participants is a priority. Sharing IPD may expose sensitive information that, even when de-identified, can be traced back to individuals. Furthermore, the complexity of the data makes sharing challenging without the risk of misunderstandings or misinterpretations, which could compromise the integrity of the research. Sharing IPD without the explicit consent of participants may violate ethical principles of respect and protection. There is also a need to comply with regulatory guidelines governing data sharing to avoid potential legal issues. Finally, the focus will be on disseminating aggregated results that can benefit the scientific community and the public without compromising individual privacy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 21 months is below that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 15, 2024
StartActual
Mar 14, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06640283
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Responsible party
Maria del Pilar Estevez Diz (Oncologist, Principal Investigator, Instituto do Cancer do Estado de São Paulo) — Principal investigator
First posted
Oct 15, 2024
Start date
Mar 14, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 24, 2025

Study contacts

Research Center, Assistant
Contact
icesp.pesqclinica@hc.fm.usp.br
+55 11 3893-3566
Maria DP Estevez Diz, Doctor
principal investigator · Oncologist

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion